Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AX200: Additional Phase IIa data

Additional data from the double-blind, placebo-controlled, German Phase IIa AXIS trial in 44 patients

Read the full 143 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE